Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA ...

Medical imaging routinely used in cancer care may hold far more biological information than previously thought.

A research team led by the Medical University of Vienna has demonstrated in a recent study that the biological characteristics of a subgroup of head and neck tumors - which are very aggressive in many ...

Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment.

Prognosis is extremely poor for patients with head and neck squamous cell carcinoma (HNSCC), which accounts for around 90% of all head and neck cancer. Especially in the more aggressive subtype of ...

Medical imaging routinely used in cancer care may hold far more biological information than previously thought. An international study involving Umeå ...

Despite a higher incidence of poor outcomes with squamous cell carcinoma tumors on the scalp, it was the lip and temple that emerged as highest risk after adjustments for other factors.

Patients who received neoadjuvant systemic therapy followed by surgical resection for mucosal HNSCC in the US National Cancer Database (2004-2022) were evaluated using 1:5 propensity score matching to ...